Sol-Gel Technologies Ltd.

NasdaqCM: SLGL · Real-Time Price · USD
80.49
+3.10 (4.01%)
At close: Aug 25, 2026, 10:42 AM

The price, the headline numbers and the latest news, in one place.

Sol-Gel Technologies Ltd. (SLGL) Stock Price, Analysis & Data

4.01%
Bid79.86
Market Cap263.12M
Revenue (ttm)1.79M
Net Income (ttm)-16.34M
1.16
-5.62
n/a
-10.45
P/B (ttm)5.48
P/S (ttm)145.52
Earnings DateMay 1, 2026
Ask82.5
Volume30,241
Avg. Volume (20D)44,988
Open78.88
Previous Close77.39
Day's Range78.88 - 81.10
52-Week Range20.10 - 97.97
AnalystStrong Buy
Price Target195 (142.27%)
Dividendsn/a
Ex-Dividend Daten/a

About SLGL

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It als...

Industry Biotechnology
Sector Healthcare
IPO Date Feb 1, 2018
Employees 28
Stock Exchange NasdaqCM
Ticker Symbol SLGL
Full Company Profile

Financial Performance

In 2025, Sol-Gel's revenue was 19.39M, an increase of 68.04% compared to the previous year's 11.54M. Earnings were -6.13M, a decrease of -42.09%.

Financial Statements

Analyst Forecast

According to 3 analyst ratings, the average rating for SLGL stock is "Strong Buy". The 12-month stock price forecast is 195, which is upside of 142.27% from the latest price.

Stock Forecasts

Earnings Surprise

Sol-Gel has released their quarterly earnings on Aug 20, 2026:
  • Revenue of $108K misses estimates by $0, with -89.52% YoY decline.
  • EPS of -1.13 exceeds estimates by 1.18, with -127.10% YoY decline.
Sol-Gel Technologies Ltd. is scheduled to release its earnings on May 1, 2026, before market opens.
Analysts project revenue of ... Upgrade